BACKGROUND: Antibodies to human leukocyte antigens (HLA) in donated blood have been implicated as a cause of transfusion-related acute lung injury (TRALI). A potential measure to reduce the risk of TRALI includes screening plateletpheresis donors for HLA antibodies. The prevalence of HLA antibodies and their relationship to previous transfusion or pregnancy in blood donors was determined. STUDY DESIGN AND METHODS: A total of 8171 volunteer blood donors were prospectively recruited by six US blood centers from December 2006 to May 2007. Donors provided a detailed history of pregnancy and transfusion and a sample for HLA Class I and II antibody testing by multiantigen bead flow analysis. RESULTS: A total of 8171 donors were enrolled; 7920 (96.9%) had valid HLA antibody test results and 7841 (99%) of those had complete pregnancy and transfusion information. The prevalence of any HLA antibody was similar in nontransfused (n = 1138) and transfused (n = 895) men, 1.0% versus 1.7% (p = 0.16). HLA antibodies were detected in 17.3% of all female donors (n = 5834) and in 24.4% of those with a history of previous pregnancy (n = 3992). The prevalence of HLA antibodies increased in women with greater numbers of pregnancy: 1.7% (zero), 11.2% (one), 22.5% (two), 27.5% (three), and 32.2% (four or more pregnancies; p < 0.0001). CONCLUSION: HLA Class I and Class II antibodies are detectable at low prevalence in male donors regardless of transfusion and in female donors without known immunizing events. The prevalence of HLA antibodies increases significantly with more pregnancies. These data will allow blood centers to estimate the impact of HLA antibody testing as a potential TRALI risk reduction measure.
BACKGROUND: Antibodies to human leukocyte antigens (HLA) in donated blood have been implicated as a cause of transfusion-related acute lung injury (TRALI). A potential measure to reduce the risk of TRALI includes screening plateletpheresis donors for HLA antibodies. The prevalence of HLA antibodies and their relationship to previous transfusion or pregnancy in blood donors was determined. STUDY DESIGN AND METHODS: A total of 8171 volunteer blood donors were prospectively recruited by six US blood centers from December 2006 to May 2007. Donors provided a detailed history of pregnancy and transfusion and a sample for HLA Class I and II antibody testing by multiantigen bead flow analysis. RESULTS: A total of 8171 donors were enrolled; 7920 (96.9%) had valid HLA antibody test results and 7841 (99%) of those had complete pregnancy and transfusion information. The prevalence of any HLA antibody was similar in nontransfused (n = 1138) and transfused (n = 895) men, 1.0% versus 1.7% (p = 0.16). HLA antibodies were detected in 17.3% of all female donors (n = 5834) and in 24.4% of those with a history of previous pregnancy (n = 3992). The prevalence of HLA antibodies increased in women with greater numbers of pregnancy: 1.7% (zero), 11.2% (one), 22.5% (two), 27.5% (three), and 32.2% (four or more pregnancies; p < 0.0001). CONCLUSION: HLA Class I and Class II antibodies are detectable at low prevalence in male donors regardless of transfusion and in female donors without known immunizing events. The prevalence of HLA antibodies increases significantly with more pregnancies. These data will allow blood centers to estimate the impact of HLA antibody testing as a potential TRALI risk reduction measure.
Authors: Steven Kleinman; Tim Caulfield; Penny Chan; Robertson Davenport; Janice McFarland; Susan McPhedran; Maureen Meade; Douglas Morrison; Thomas Pinsent; Pierre Robillard; Peter Slinger Journal: Transfusion Date: 2004-12 Impact factor: 3.157
Authors: Erik A Scott; Karen S Schlumpf; Sunitha M Mathew; Alan E Mast; Michael P Busch; Jerome L Gottschall Journal: Transfusion Date: 2010-09 Impact factor: 3.157
Authors: Jerome L Gottschall; Darrell J Triulzi; Brian Curtis; Ram M Kakaiya; Michael P Busch; Philip J Norris; Simone A Glynn; Danielle Carrick; David J Wright; Steve Kleinman Journal: Transfusion Date: 2010-10-26 Impact factor: 3.157
Authors: Pearl Toy; Ognjen Gajic; Peter Bacchetti; Mark R Looney; Michael A Gropper; Rolf Hubmayr; Clifford A Lowell; Philip J Norris; Edward L Murphy; Richard B Weiskopf; Gregory Wilson; Monique Koenigsberg; Deanna Lee; Randy Schuller; Ping Wu; Barbara Grimes; Manish J Gandhi; Jeffrey L Winters; David Mair; Nora Hirschler; Rosa Sanchez Rosen; Michael A Matthay Journal: Blood Date: 2011-11-23 Impact factor: 22.113
Authors: JoonHo Lee; Roberto Romero; Yi Xu; Jung-Sun Kim; Ji Young Park; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Sonia S Hassan; Chong Jai Kim Journal: Am J Reprod Immunol Date: 2011-09-27 Impact factor: 3.886
Authors: Jorge A Rios; Karen S Schlumpf; Ram M Kakaiya; Darrell J Triulzi; John D Roback; Steve H Kleinman; Edward L Murphy; Jerome L Gottschall; Patricia M Carey Journal: Transfusion Date: 2010-12-23 Impact factor: 3.157
Authors: Jeremy Ryan A Peña; Susan L Saidman; Timothy C Girouard; Erin Meister; Walter H Dzik; Robert S Makar Journal: Am J Hematol Date: 2014-06-19 Impact factor: 10.047
Authors: Ram M Kakaiya; Darrell J Triulzi; David J Wright; Whitney R Steele; Steven H Kleinman; Michael P Busch; Philip J Norris; Christopher D Hillyer; Jerome L Gottschall; Jorge A Rios; Patricia Carey; Simone A Glynn Journal: Transfusion Date: 2010-01-08 Impact factor: 3.157